Downloaded 85 times
Uploaded byfondas vakalis
Vakalis breast radiotherapy
The document discusses breast cancer treatment recommendations including: - No radiation therapy is recommended for early stage DCIS or invasive breast cancer. - A tumor bed boost is recommended for higher risk patients but large trials found no survival difference with or without a boost. - Hypofractionated whole breast radiation has become a standard option based on trials showing no difference in survival outcomes compared to conventional fractionation. - Several trials investigated omitting axillary lymph node dissection or radiation with favorable results for select patient groups with low tumor burden.
More Related Content
Similar to Vakalis breast radiotherapy
Vakalis breast radiotherapy
- 1. FUZZ-IEEE 2009 Ακτινοθεραπευτής Ογκολόγος Euromedica– Αθήναιον Α Ιατρικό Κέντρο Αθηνών Βακάλης Ξενοφών
- 4.
- 7.
- 10. Breast Cancer Nomogram: DuctalCarcinoma In Situ (DCIS) Recurrence
- 11. Breast Cancer Nomogram: DuctalCarcinoma In Situ (DCIS) Recurrence
- 13. OncoTypeDX for Estimating RecurrenceRisk After Lumpectomy with No Radiation Score Any Recurrence Invasive Recurrence Low Risk 12% 5% Intermediate Risk 25% 9% High Risk 27% 19% E5194 study http://www.genomichealth.com/en-US/OncotypeDX.aspx further validation of these results is required
- 16. clinical stage I,IIA, or a subset of stage IIB disease (T2N1)
- 20.
- 21.
- 31.
- 32.
- 33.
- 34.
- 35.
- 36.
- 37.
- 38.
- 40.
- 41. SLND Negative SLN No additionalaxillary treatment necessary •Milan trial, SLN = ALND •NSABP B-32, SLN = ALND Positive SLN •Full node dissection •No Axillary treatment •ACOSOG Z0011 •IBCSG 23-01 •AMAROS
- 42.
- 43.
- 44. • High tangentfields includes most of area at risk • Superior border: Just below humeral head • Posterior border: 2 cm within the lung includes: – over 95% of SLN – over 80% of level I and II axilla Schlembach, Int J Rad Oncol Biol Phys, 2001
- 45.
- 46. Standard ALND RadiotherapyP-value 5-year Axillary Recurrence rate 0.54% (4/744) 1.03% (7/681) 5-year Overall Survival Rate 93.3 92.5 0.338 5-year Disease-free Survival Rate 86.9 82.7 0.179 ASCO 2013
- 47.
- 48.
- 50. Limit LRR 15%for RT
- 52. G.M. Freedman ASTROSpring Refresher Course 2013
- 55. G.M. Freedman ASTROSpring Refresher Course 2013
- 56.
- 57.
- 58.
- 59. www.wondershare.com No difference inoverall survival, breast cancer mortality, or disease-free survival at 10 years
- 60. Bartelink H, etal., J Clin Oncol 2007 Jones, H. A. et al. J Clin Oncol 2009
- 61.
- 62. • The breastshould receive a dose of 45-50 Gy in 1.8 – 2 Gy per fraction, 42.5 Gy at 2.66 Gy per fraction. • A boost to the tumor bed is recommended for patients in higher risk for local failure: – Age < 50 – Positive lymph nodes – LVI – Close margins
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71.
- 72.
- 73.
- 74.
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 85. A lot ofsubgroups No RT of breast in DCIS No RT of breast in early stage of invasive ca No boost Hypofractionated RT of whole breast Accelerated Partial RT
- 86. THANKS FOR YOURATTENTION!